首页 > 最新文献

Phytomedicine最新文献

英文 中文
Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review 天竺葵——从民族药理学到循证医学:系统综述。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-23 DOI: 10.1016/j.phymed.2026.157880
Oksana Honchar , Olha Мykhailenko , Olha Holovchenko , Victoriya Georgiyants

Background

Pelargonium sidoides DC. (Geraniaceae) has a long history of traditional use among indigenous peoples of Southern Africa for treating respiratory and gastrointestinal disorders. Its transformation into the modern pharmaceutical product Umckaloabo (EPs® 7630) exemplifies the transition from traditional medicine to evidence-based therapeutics.

Purpose

To provide a systematic analysis of P. sidoides, spanning from its botanical characteristics and ethnobotanical roots to its development as a regulated phytomedicine. The review focuses on the plant's unique phytochemical profile and provides a detailed synthesis of its molecular and systems-biological mechanisms of action, cultivation sustainability, and clinical efficacy in managing respiratory tract infections.

Study design and methods

A systematic search was conducted across PubMed, Scopus, and Cochrane Library up to December 2025 following PRISMA guidelines. Sources included scientific articles, pharmacopoeias, patents, and ethnobotanical records in English and Ukrainian.

Results

The systematic synthesis of identified records characterizes the chemical diversity of P. sidoides, focusing on specialized metabolites such as highly substituted benzopyranones, prodelphinidins, and unique coumarin sulfates. The review discusses modern cultivation practices, sustainability issues, and comparative extraction techniques, while analytical methods such as HPLC, LC-MS, and TLC for standardization are summarized. The pharmacological profile is defined by multi-target activity, encompassing immunomodulatory, antibacterial, and antiviral effects, including studies on SARS-CoV-2 and other respiratory pathogens. Analysis of available clinical data validates the therapeutic use of P. sidoides root preparations for managing acute bronchitis, rhinosinusitis, and tonsillopharyngitis.

Conclusion

This study demonstrates that the integration of P. sidoides into modern healthcare is supported by the synergy between traditional knowledge and molecular and clinical validation. By mapping the developmental trajectory — from wild harvesting to systems-biological evidence — this review identifies P. sidoides as a model for the pharmaceutical translation of ethnobotanical resources into standardized, evidence-based phytomedicines.
背景:天竺葵。(天竺葵科)在非洲南部的土著人民中有着悠久的传统使用历史,用于治疗呼吸和胃肠疾病。它向现代医药产品Umckaloabo (EPs®7630)的转变体现了从传统医学到循证治疗的转变。目的:从植物学特征、民族植物学根源到其作为植物药物的发展,对草内酯进行系统的分析。本文综述了该植物独特的植物化学特征,并详细介绍了其分子和系统生物学作用机制、培养可持续性和治疗呼吸道感染的临床疗效。研究设计和方法:系统检索PubMed、Scopus和Cochrane图书馆,截止到2025年12月,遵循PRISMA指南。来源包括科学文章,药典,专利,和民族植物学记录在英语和乌克兰。结果:系统合成的鉴定记录表征了P. sidoides的化学多样性,重点是专门的代谢物,如高取代的苯并吡喃酮、prodelphinidins和独特的香豆素硫酸盐。本文讨论了现代栽培方法、可持续性问题和比较提取技术,并对HPLC、LC-MS和TLC等标准化分析方法进行了综述。药理学概况由多靶点活性定义,包括免疫调节、抗菌和抗病毒作用,包括对SARS-CoV-2和其他呼吸道病原体的研究。对现有临床数据的分析验证了赛多甙根制剂治疗急性支气管炎、鼻鼻窦炎和扁桃体咽炎的疗效。结论:本研究表明,传统知识与分子和临床验证之间的协同作用支持了P. sidoides融入现代医疗保健。通过绘制从野生收获到系统生物学证据的发展轨迹,本综述确定了P. sidoides作为将民族植物资源转化为标准化、循证植物药物的模型。
{"title":"Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review","authors":"Oksana Honchar ,&nbsp;Olha Мykhailenko ,&nbsp;Olha Holovchenko ,&nbsp;Victoriya Georgiyants","doi":"10.1016/j.phymed.2026.157880","DOIUrl":"10.1016/j.phymed.2026.157880","url":null,"abstract":"<div><h3>Background</h3><div><em>Pelargonium sidoides</em> DC. (Geraniaceae) has a long history of traditional use among indigenous peoples of Southern Africa for treating respiratory and gastrointestinal disorders. Its transformation into the modern pharmaceutical product Umckaloabo (EPs® 7630) exemplifies the transition from traditional medicine to evidence-based therapeutics.</div></div><div><h3>Purpose</h3><div>To provide a systematic analysis of <em>P. sidoides</em>, spanning from its botanical characteristics and ethnobotanical roots to its development as a regulated phytomedicine. The review focuses on the plant's unique phytochemical profile and provides a detailed synthesis of its molecular and systems-biological mechanisms of action, cultivation sustainability, and clinical efficacy in managing respiratory tract infections.</div></div><div><h3>Study design and methods</h3><div>A systematic search was conducted across PubMed, Scopus, and Cochrane Library up to December 2025 following PRISMA guidelines. Sources included scientific articles, pharmacopoeias, patents, and ethnobotanical records in English and Ukrainian.</div></div><div><h3>Results</h3><div>The systematic synthesis of identified records characterizes the chemical diversity of <em>P. sidoides</em>, focusing on specialized metabolites such as highly substituted benzopyranones, prodelphinidins, and unique coumarin sulfates. The review discusses modern cultivation practices, sustainability issues, and comparative extraction techniques, while analytical methods such as HPLC, LC-MS, and TLC for standardization are summarized. The pharmacological profile is defined by multi-target activity, encompassing immunomodulatory, antibacterial, and antiviral effects, including studies on SARS-CoV-2 and other respiratory pathogens. Analysis of available clinical data validates the therapeutic use of <em>P. sidoides</em> root preparations for managing acute bronchitis, rhinosinusitis, and tonsillopharyngitis.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that the integration of <em>P. sidoides</em> into modern healthcare is supported by the synergy between traditional knowledge and molecular and clinical validation. By mapping the developmental trajectory — from wild harvesting to systems-biological evidence — this review identifies <em>P. sidoides</em> as a model for the pharmaceutical tran<strong>s</strong>lation of ethnobotanical resources into standardized, evidence-based phytomedicines.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"153 ","pages":"Article 157880"},"PeriodicalIF":8.3,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ferroptosis under fire: cannabidiol mitigates iron-dependent injury in differentiated human neuroblastoma cells following oxygen-glucose deprivation 火灾下的铁下垂:大麻二酚减轻氧葡萄糖剥夺后分化的人神经母细胞瘤细胞的铁依赖性损伤。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157868
Maciej Klimiuk , Małgorzata Jefimow , Hanna Kletkiewicz

Background

Perinatal hypoxia–ischemia is a major cause of long-term neurological impairments in newborns, with ferroptosis recognized as a key mechanism of injury. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid with antioxidant and neuroprotective properties. CBD is a potential modulator of hypoxic–ischemic brain damage, however its effects on ferroptosis-related pathways remain unclear.

Purpose

In this study, we examined whether CBD can alleviate ferroptosis-associated damage in differentiated human neuroblastoma (neuron-like SH-SY5Y) cell model of hypoxic–ischemic injury.

Study Design

Differentiated human neuroblastoma cells were exposed to oxygen–glucose deprivation (OGD) to simulate hypoxic–ischemic conditions.

Methods

Neuron-like SH-SY5Y cells were subjected to OGD to induce hypoxic–ischemic injury. CBD was applied to assess its neuroprotective effects. Oxidative stress markers, antioxidant enzyme activity, transcription factor activation Nrf2 (nuclear factor erythroid 2-related factor 2), iron metabolism proteins (ferroportin), hypoxia-inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) expression were evaluated.

Results

CBD application significantly reduced oxidative stress by improving antioxidant capacity and lowering total oxidant status. CBD also preserved the expression and enzymatic activity of glutathione peroxidase 4, a central enzyme protecting against lipid peroxidation, and enhanced the activation of Nrf2, a key regulator of antioxidant defence. Additionally, CBD prevented OGD-induced downregulation of ferroportin, potentially supporting iron efflux and reducing ferroptotic risk. HIF-1α and its downstream target VEGF were upregulated under hypoxic conditions, and CBD further enhanced VEGF expression.

Conclusion

CBD mitigates ferroptosis by modulating redox balance, antioxidant defence, and iron metabolism, supporting its potential role as a therapeutic strategy for neonatal hypoxic–ischemic brain injury.
背景:围产期缺氧缺血是新生儿长期神经功能损伤的主要原因,而铁下垂被认为是损伤的关键机制。大麻二酚(CBD)是一种具有抗氧化和神经保护特性的非精神活性植物大麻素。CBD是缺氧缺血性脑损伤的潜在调节剂,但其对铁中毒相关途径的影响尚不清楚。目的:在本研究中,我们研究了CBD是否可以减轻分化的人神经母细胞瘤(神经元样SH-SY5Y)细胞模型缺氧缺血性损伤的铁中毒相关损伤。研究设计:将分化的人类神经母细胞瘤细胞暴露于缺氧-葡萄糖剥夺(OGD)中以模拟缺氧-缺血状态。方法:对神经元样SH-SY5Y细胞进行OGD诱导缺氧缺血性损伤。应用CBD评价其神经保护作用。评估氧化应激标志物、抗氧化酶活性、转录因子激活Nrf2(核因子-红细胞2相关因子2)、铁代谢蛋白(铁转运蛋白)、缺氧诱导因子1α (HIF-1α)和血管内皮生长因子(VEGF)的表达。结果:CBD通过提高抗氧化能力和降低总氧化状态显著降低氧化应激。CBD还保持了谷胱甘肽过氧化物酶4(一种防止脂质过氧化的中心酶)的表达和酶活性,并增强了抗氧化防御的关键调节因子Nrf2的激活。此外,CBD可防止ogd诱导的铁转运蛋白下调,可能支持铁外排并降低铁迁移风险。缺氧条件下HIF-1α及其下游靶点VEGF表达上调,CBD进一步增强VEGF表达。结论:CBD通过调节氧化还原平衡、抗氧化防御和铁代谢来减轻铁下沉,支持其作为新生儿缺氧缺血性脑损伤治疗策略的潜在作用。
{"title":"Ferroptosis under fire: cannabidiol mitigates iron-dependent injury in differentiated human neuroblastoma cells following oxygen-glucose deprivation","authors":"Maciej Klimiuk ,&nbsp;Małgorzata Jefimow ,&nbsp;Hanna Kletkiewicz","doi":"10.1016/j.phymed.2026.157868","DOIUrl":"10.1016/j.phymed.2026.157868","url":null,"abstract":"<div><h3>Background</h3><div>Perinatal hypoxia–ischemia is a major cause of long-term neurological impairments in newborns, with ferroptosis recognized as a key mechanism of injury. Cannabidiol (CBD) is a non-psychoactive phytocannabinoid with antioxidant and neuroprotective properties. CBD is a potential modulator of hypoxic–ischemic brain damage, however its effects on ferroptosis-related pathways remain unclear.</div></div><div><h3>Purpose</h3><div>In this study, we examined whether CBD can alleviate ferroptosis-associated damage in differentiated human neuroblastoma (neuron-like SH-SY5Y) cell model of hypoxic–ischemic injury.</div></div><div><h3>Study Design</h3><div>Differentiated human neuroblastoma cells were exposed to oxygen–glucose deprivation (OGD) to simulate hypoxic–ischemic conditions.</div></div><div><h3>Methods</h3><div>Neuron-like SH-SY5Y cells were subjected to OGD to induce hypoxic–ischemic injury. CBD was applied to assess its neuroprotective effects. Oxidative stress markers, antioxidant enzyme activity, transcription factor activation Nrf2 (nuclear factor erythroid 2-related factor 2), iron metabolism proteins (ferroportin), hypoxia-inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) expression were evaluated.</div></div><div><h3>Results</h3><div>CBD application significantly reduced oxidative stress by improving antioxidant capacity and lowering total oxidant status. CBD also preserved the expression and enzymatic activity of glutathione peroxidase 4, a central enzyme protecting against lipid peroxidation, and enhanced the activation of Nrf2, a key regulator of antioxidant defence. Additionally, CBD prevented OGD-induced downregulation of ferroportin, potentially supporting iron efflux and reducing ferroptotic risk. HIF-1α and its downstream target VEGF were upregulated under hypoxic conditions, and CBD further enhanced VEGF expression.</div></div><div><h3>Conclusion</h3><div>CBD mitigates ferroptosis by modulating redox balance, antioxidant defence, and iron metabolism, supporting its potential role as a therapeutic strategy for neonatal hypoxic–ischemic brain injury.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"152 ","pages":"Article 157868"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146047170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis 臭椿酮劫持ERK/NF-κB级联减缓骨质疏松症的破骨细胞发生。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157870
Xiaodi Zhang , Jianning Kang , Qianyun Wang , Ying Zhang , Jianhao Jiang , Zhengxin Jin , Ce Zhang , Zhengfang Sun , Zheng Li , Ronghan Liu , Bin Ning

Background

Osteoporosis is a serious bone disease, it can eventually lead to disability. However, no safe or effective intervention is currently available. Therefore, there is an urgent need to develop effective drugs that reduce bone loss and treat osteoporosis.

Purpose

This study aimed to ascertain the potential of ailanthone (AIL), a natural small molecule, as a therapeutic drug for alleviating the progression of osteoporosis.

Methods

By screening of a library of natural compounds; in vitro assays for examining the inhibition of osteoclast differentiation by AIL: in vivo assays for detecting the anti-osteoclastogenesis activity of AIL using mimicking progressive bone loss mice model and the other simulating postmenopausal osteoporosis mice model. Identification and characterisation of the binding of AIL to extracellular signal-regulated kinase 2 (ERK2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, microscale thermophoresis; various assays for examining the dependence of AIL’s anti-osteoclastogenesis activity on ERK2.

Results

This study discovered AIL, a potent inhibitor of osteoclastogenesis from a screened library of natural compounds. In vitro studies demonstrated that AIL attenuated RANKL-induced osteoclast differentiation. Additionally, AIL administration decreased osteoclast populations and their bone-degrading activities. AIL was discovered to target ERK2, specifically the Methionine-108 (Met-108) site, which is presumed to contribute to its anti-osteoclastogenic properties. Further analysis indicated that AIL blocks ERK1/2 phosphorylation, thereby influencing the NF-κB signaling cascade.

Conclusions

Collectively, these findings demonstrate AIL, that can significantly inhibit osteoclastogenesis linked to inflammaging, opening up novel avenues for osteoporosis treatment strategies and other ERK related diseases.
背景:骨质疏松症是一种严重的骨骼疾病,它最终会导致残疾。然而,目前还没有安全或有效的干预措施。因此,迫切需要开发减少骨质流失和治疗骨质疏松症的有效药物。目的:研究天然小分子臭椿酮(ailanthone, AIL)作为缓解骨质疏松症进展的治疗药物的潜力。方法:筛选天然化合物文库;体外实验检测AIL对破骨细胞分化的抑制作用;体内实验采用模拟进行性骨质流失小鼠模型和模拟绝经后骨质疏松小鼠模型检测AIL抗破骨细胞生成活性。利用药物亲和响应靶稳定性测定、蛋白质组学、细胞热移测定、微尺度热电泳鉴定和表征AIL与细胞外信号调节激酶2 (ERK2)的结合;各种检测AIL抗破骨细胞生成活性对ERK2依赖性的实验。结果:本研究从筛选的天然化合物文库中发现了AIL,一种有效的破骨细胞生成抑制剂。体外研究表明,AIL可减弱rankl诱导的破骨细胞分化。此外,给药可减少破骨细胞数量及其骨降解活性。发现AIL靶向ERK2,特别是蛋氨酸-108 (Met-108)位点,这被认为有助于其抗破骨细胞生成特性。进一步分析表明,AIL阻断ERK1/2磷酸化,从而影响NF-κB信号级联。结论:总的来说,这些发现表明,AIL可以显著抑制与炎症相关的破骨细胞生成,为骨质疏松症和其他ERK相关疾病的治疗策略开辟了新的途径。
{"title":"Ailanthone hijacks ERK/NF-κB cascade to attenuate osteoclastogenesis for osteoporosis","authors":"Xiaodi Zhang ,&nbsp;Jianning Kang ,&nbsp;Qianyun Wang ,&nbsp;Ying Zhang ,&nbsp;Jianhao Jiang ,&nbsp;Zhengxin Jin ,&nbsp;Ce Zhang ,&nbsp;Zhengfang Sun ,&nbsp;Zheng Li ,&nbsp;Ronghan Liu ,&nbsp;Bin Ning","doi":"10.1016/j.phymed.2026.157870","DOIUrl":"10.1016/j.phymed.2026.157870","url":null,"abstract":"<div><h3>Background</h3><div>Osteoporosis is a serious bone disease, it can eventually lead to disability. However, no safe or effective intervention is currently available. Therefore, there is an urgent need to develop effective drugs that reduce bone loss and treat osteoporosis.</div></div><div><h3>Purpose</h3><div>This study aimed to ascertain the potential of ailanthone (AIL), a natural small molecule, as a therapeutic drug for alleviating the progression of osteoporosis.</div></div><div><h3>Methods</h3><div>By screening of a library of natural compounds; <em>in vitro</em> assays for examining the inhibition of osteoclast differentiation by AIL: <em>in vivo</em> assays for detecting the anti-osteoclastogenesis activity of AIL using mimicking progressive bone loss mice model and the other simulating postmenopausal osteoporosis mice model. Identification and characterisation of the binding of AIL to extracellular signal-regulated kinase 2 (ERK2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, microscale thermophoresis; various assays for examining the dependence of AIL’s anti-osteoclastogenesis activity on ERK2.</div></div><div><h3>Results</h3><div>This study discovered AIL, a potent inhibitor of osteoclastogenesis from a screened library of natural compounds. <em>In vitro</em> studies demonstrated that AIL attenuated RANKL-induced osteoclast differentiation. Additionally, AIL administration decreased osteoclast populations and their bone-degrading activities. AIL was discovered to target ERK2, specifically the Methionine-108 (Met-108) site, which is presumed to contribute to its anti-osteoclastogenic properties. Further analysis indicated that AIL blocks ERK1/2 phosphorylation, thereby influencing the NF-κB signaling cascade.</div></div><div><h3>Conclusions</h3><div>Collectively, these findings demonstrate AIL, that can significantly inhibit osteoclastogenesis linked to inflammaging, opening up novel avenues for osteoporosis treatment strategies and other ERK related diseases.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"152 ","pages":"Article 157870"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gualou Huoxue Jiedu Decoction inhibits VSMC phenotypic switching to alleviate atherosclerosis via promoting Mfap4 DNA methylation 瓜楼活血解毒汤通过促进Mfap4 DNA甲基化抑制VSMC表型转换,缓解动脉粥样硬化
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157881
Yiming Li , Wenxin Zou , Yan Zhang , Zhongwen Qi , Qing Wang , Zijun Jia , Qingbing Zhou , Fengqin Xu

Background

Atherosclerosis (AS) is a chronic disease characterized by lipid deposition in the vascular intima. As the pathological basis of cardiovascular diseases, AS represents a major contributor to global morbidity and mortality. While Gualou Huoxue Jiedu Decoction (GHJD) has been widely used in clinical practice for the treatment of AS, the molecular mechanisms remain unclear.

Purpose

To investigate the anti-atherosclerotic effects and underlying mechanisms of GHJD.

Methods

Apoe-/- mice were treated with GHJD to evaluate its effects on plaque formation, lipid profiles, and inflammatory responses. The main compounds in GHJD were identified using UHPLC-Q-Orbitrap HRMS. Integrated analyses of network pharmacology, methyl-capture sequencing (MC-seq), and RNA-seq were performed to elucidate the molecular mechanisms of GHJD. In vitro experiments were conducted to validate its mechanism of action.

Results

GHJD alleviated plaque formation, improved lipid metabolism, and suppressed inflammation in vivo. Multi-omics analysis revealed that DNA methylation of Mfap4 could be a pivotal target of GHJD efficacy. In vitro assays confirmed that GHJD suppressed Mfap4 transcription and translation, leading to downregulation of integrin receptor family expression and inhibition of VSMC phenotypic switching.

Conclusion

GHJD exerts anti-atherosclerotic effects through epigenetic modulation of Mfap4 and downstream integrin/FAK signaling pathway, thereby inhibiting VSMC phenotypic switching. These findings provide pharmacological evidence supporting GHJD as a potential therapy for AS and, for the first time, validate MFAP4 as a pharmacological target, offering new insights into AS prevention and treatment.
背景动脉粥样硬化(AS)是一种以血管内膜脂质沉积为特征的慢性疾病。作为心血管疾病的病理基础,As是全球发病率和死亡率的主要因素。瓜楼活血解毒汤(GHJD)已广泛应用于临床治疗AS,但其分子机制尚不清楚。目的探讨黄芪多糖的抗动脉粥样硬化作用及其机制。方法用GHJD治疗apoe -/-小鼠,评估其对斑块形成、脂质谱和炎症反应的影响。采用UHPLC-Q-Orbitrap HRMS对其主要成分进行了鉴定。通过网络药理学、甲基捕获测序(MC-seq)和RNA-seq的综合分析来阐明GHJD的分子机制。体外实验验证其作用机制。结果ghjd在体内减轻斑块形成,改善脂质代谢,抑制炎症反应。多组学分析显示,Mfap4的DNA甲基化可能是GHJD疗效的关键靶点。体外实验证实,GHJD抑制Mfap4的转录和翻译,导致整合素受体家族表达下调,抑制VSMC表型转换。结论hjd通过表观遗传调控Mfap4及下游整合素/FAK信号通路发挥抗动脉粥样硬化作用,从而抑制VSMC表型转换。这些发现为GHJD作为as的潜在治疗方法提供了药理学证据,并首次验证了MFAP4作为as的药理学靶点,为as的预防和治疗提供了新的见解。
{"title":"Gualou Huoxue Jiedu Decoction inhibits VSMC phenotypic switching to alleviate atherosclerosis via promoting Mfap4 DNA methylation","authors":"Yiming Li ,&nbsp;Wenxin Zou ,&nbsp;Yan Zhang ,&nbsp;Zhongwen Qi ,&nbsp;Qing Wang ,&nbsp;Zijun Jia ,&nbsp;Qingbing Zhou ,&nbsp;Fengqin Xu","doi":"10.1016/j.phymed.2026.157881","DOIUrl":"10.1016/j.phymed.2026.157881","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis (AS) is a chronic disease characterized by lipid deposition in the vascular intima. As the pathological basis of cardiovascular diseases, AS represents a major contributor to global morbidity and mortality. While Gualou Huoxue Jiedu Decoction (GHJD) has been widely used in clinical practice for the treatment of AS, the molecular mechanisms remain unclear.</div></div><div><h3>Purpose</h3><div>To investigate the anti-atherosclerotic effects and underlying mechanisms of GHJD.</div></div><div><h3>Methods</h3><div>Apoe<sup>-/-</sup> mice were treated with GHJD to evaluate its effects on plaque formation, lipid profiles, and inflammatory responses. The main compounds in GHJD were identified using UHPLC-Q-Orbitrap HRMS. Integrated analyses of network pharmacology, methyl-capture sequencing (MC-seq), and RNA-seq were performed to elucidate the molecular mechanisms of GHJD. In vitro experiments were conducted to validate its mechanism of action.</div></div><div><h3>Results</h3><div>GHJD alleviated plaque formation, improved lipid metabolism, and suppressed inflammation in vivo. Multi-omics analysis revealed that DNA methylation of Mfap4 could be a pivotal target of GHJD efficacy. In vitro assays confirmed that GHJD suppressed <em>Mfap4</em> transcription and translation, leading to downregulation of integrin receptor family expression and inhibition of VSMC phenotypic switching.</div></div><div><h3>Conclusion</h3><div>GHJD exerts anti-atherosclerotic effects through epigenetic modulation of <em>Mfap4</em> and downstream integrin/FAK signaling pathway, thereby inhibiting VSMC phenotypic switching. These findings provide pharmacological evidence supporting GHJD as a potential therapy for AS and, for the first time, validate MFAP4 as a pharmacological target, offering new insights into AS prevention and treatment.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"153 ","pages":"Article 157881"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atractyloside-A ameliorates spleen deficiency diarrhea in mice via modulating Lactobacillus johnsonii-butyric acid-GPR43 axis and NF-κB -NLRP3 signaling pathway 白术皂苷a通过调节约氏乳酸菌-丁酸- gpr43轴和NF-κB -NLRP3信号通路改善小鼠脾虚腹泻
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157875
Yangxin Xiao , Chang Ke , Dongpeng Wang , Niping Chen , Gaoyuan Chen , Linghang Qu , Yanju Liu
<div><h3>Background</h3><div>Spleen deficiency diarrhea (SDD) is regarded as a common gastrointestinal dysfunction in Traditional Chinese Medicine (TCM), which may lead to intestinal barrier damage and trigger intestinal inflammation. Previous studies have shown that Atractylenolide-A (AA) can effectively treat SDD by regulating intestinal flora. However, it remains uncertain whether AA can increase the levels of short-chain fatty acids (SCFAs) by restoring intestinal microbiota, thereby activating specific signaling pathways to regulate target protein and subsequently alleviate issues related to intestinal barrier function and inflammation.</div></div><div><h3>Purpose</h3><div>This study focused on examining the function of the signaling pathway involving microbiota, SCFAs, and G protein-coupled receptors (GPRs) in the anti-SDD effects of AA.</div></div><div><h3>Methods</h3><div>The effects of AA on the Senna (SE) - induced SDD mouse model were assessed through various methods, including diarrhea scoring, H&E staining, qRT-PCR, and ELISA analysis. Subsequently, targeted metabolomics was employed to pinpoint essential metabolites that influence the intestinal microenvironment, while western blotting was utilized to measure the expression of GPRs and the NLRP3 inflammasome. Additionally, experiments involving dietary supplementation with SCFAs and AAV-shGPR43 were performed to determine whether the pharmacological effects of AA operate through SCFAs and rely on GPR43. Key bacterial species that play a role in AA’s modulation of SCFAs’ pharmacological effects were identified through metagenomic sequencing and single-strain experiments.</div></div><div><h3>Results</h3><div>The findings of this research revealed that AA is capable of significantly reducing the intestinal inflammatory response, reversing damage to mucin synthesis, and alleviating the pathological symptoms linked to SDD. Furthermore, the use of <em>Lactobacillus johnsonii</em>, sodium butyrate (NaB), and SCFAs individually can lead to notable enhancements in various phenotypes related to SDD. In terms of mechanism, AA achieves its anti-SDD effects by elevating the levels of <em>Lactobacillus johnsonii</em>, facilitating the concentration of butyric acid, boosting GPR43 expression, and modulating the TLR4/NF-κB signaling pathway, which in turn inhibits the assembly of the NLRP3 inflammasome. Nonetheless, following the injection of AAV-shGPR43, the advantageous effects of both AA and NaB were negated, underscoring the significance of this target.</div></div><div><h3>Conclusions</h3><div>Gut microbiota-SCFAs-GPRs axis and NF-κB-NLRP3 pathway involve in the alleviation of diarrhea and inflammation in SDD mice intervened with AA, AA promotes the production of butyrate by influencing <em>Lactobacillus johnsonii</em>, stimulates GPR43, and suppresses the formation of the NLRP3 inflammasome via the regulation of the TLR4/NF-κB signaling pathway, which subsequently improves SDD in mice.</di
脾虚性腹泻(SDD)是一种常见的胃肠功能障碍,可导致肠道屏障损伤,引发肠道炎症。既往研究表明,苍术内酯a (Atractylenolide-A, AA)可通过调节肠道菌群有效治疗SDD。然而,AA是否可以通过恢复肠道菌群来增加短链脂肪酸(SCFAs)的水平,从而激活特定的信号通路来调节目标蛋白,从而缓解肠道屏障功能和炎症相关问题,目前尚不确定。目的探讨微生物群、短链脂肪酸和G蛋白偶联受体(GPRs)在AA抗sdd中的作用。方法采用腹泻评分、H&;E染色、qRT-PCR、ELISA等方法评价AA对泻泻草(SE)诱导的SDD小鼠模型的影响。随后,我们利用靶向代谢组学来确定影响肠道微环境的必需代谢物,同时利用western blotting来测量GPRs和NLRP3炎症小体的表达。此外,我们还通过膳食补充SCFAs和AAV-shGPR43的实验来确定AA的药理作用是否通过SCFAs发挥作用,并依赖于GPR43。通过宏基因组测序和单菌株实验,确定了参与AA调控SCFAs药理作用的关键菌种。结果本研究结果显示,AA能够显著降低肠道炎症反应,逆转粘蛋白合成损伤,缓解SDD相关病理症状。此外,单独使用约氏乳杆菌、丁酸钠(NaB)和SCFAs可以显著增强与SDD相关的各种表型。从机制上看,AA的抗sdd作用是通过提高约氏乳杆菌水平,促进丁酸浓度,促进GPR43表达,调节TLR4/NF-κB信号通路,从而抑制NLRP3炎性体的组装来实现的。然而,在注射AAV-shGPR43后,AA和NaB的优势作用均被否定,强调了该靶点的重要性。结论肠道微生物群- scfas - gprs轴和NF-κB-NLRP3通路参与AA干预SDD小鼠腹泻和炎症的缓解,AA通过影响约氏乳杆菌促进丁酸盐的产生,刺激GPR43,并通过调节TLR4/NF-κB信号通路抑制NLRP3炎症小体的形成,从而改善小鼠SDD。
{"title":"Atractyloside-A ameliorates spleen deficiency diarrhea in mice via modulating Lactobacillus johnsonii-butyric acid-GPR43 axis and NF-κB -NLRP3 signaling pathway","authors":"Yangxin Xiao ,&nbsp;Chang Ke ,&nbsp;Dongpeng Wang ,&nbsp;Niping Chen ,&nbsp;Gaoyuan Chen ,&nbsp;Linghang Qu ,&nbsp;Yanju Liu","doi":"10.1016/j.phymed.2026.157875","DOIUrl":"10.1016/j.phymed.2026.157875","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Spleen deficiency diarrhea (SDD) is regarded as a common gastrointestinal dysfunction in Traditional Chinese Medicine (TCM), which may lead to intestinal barrier damage and trigger intestinal inflammation. Previous studies have shown that Atractylenolide-A (AA) can effectively treat SDD by regulating intestinal flora. However, it remains uncertain whether AA can increase the levels of short-chain fatty acids (SCFAs) by restoring intestinal microbiota, thereby activating specific signaling pathways to regulate target protein and subsequently alleviate issues related to intestinal barrier function and inflammation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;This study focused on examining the function of the signaling pathway involving microbiota, SCFAs, and G protein-coupled receptors (GPRs) in the anti-SDD effects of AA.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The effects of AA on the Senna (SE) - induced SDD mouse model were assessed through various methods, including diarrhea scoring, H&amp;E staining, qRT-PCR, and ELISA analysis. Subsequently, targeted metabolomics was employed to pinpoint essential metabolites that influence the intestinal microenvironment, while western blotting was utilized to measure the expression of GPRs and the NLRP3 inflammasome. Additionally, experiments involving dietary supplementation with SCFAs and AAV-shGPR43 were performed to determine whether the pharmacological effects of AA operate through SCFAs and rely on GPR43. Key bacterial species that play a role in AA’s modulation of SCFAs’ pharmacological effects were identified through metagenomic sequencing and single-strain experiments.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The findings of this research revealed that AA is capable of significantly reducing the intestinal inflammatory response, reversing damage to mucin synthesis, and alleviating the pathological symptoms linked to SDD. Furthermore, the use of &lt;em&gt;Lactobacillus johnsonii&lt;/em&gt;, sodium butyrate (NaB), and SCFAs individually can lead to notable enhancements in various phenotypes related to SDD. In terms of mechanism, AA achieves its anti-SDD effects by elevating the levels of &lt;em&gt;Lactobacillus johnsonii&lt;/em&gt;, facilitating the concentration of butyric acid, boosting GPR43 expression, and modulating the TLR4/NF-κB signaling pathway, which in turn inhibits the assembly of the NLRP3 inflammasome. Nonetheless, following the injection of AAV-shGPR43, the advantageous effects of both AA and NaB were negated, underscoring the significance of this target.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Gut microbiota-SCFAs-GPRs axis and NF-κB-NLRP3 pathway involve in the alleviation of diarrhea and inflammation in SDD mice intervened with AA, AA promotes the production of butyrate by influencing &lt;em&gt;Lactobacillus johnsonii&lt;/em&gt;, stimulates GPR43, and suppresses the formation of the NLRP3 inflammasome via the regulation of the TLR4/NF-κB signaling pathway, which subsequently improves SDD in mice.&lt;/di","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"152 ","pages":"Article 157875"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asperosaponin VI enhances stress resilience by activating hippocampal neural stem cells asperaponin VI通过激活海马神经干细胞增强应激恢复能力
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157874
Yu-e Liu , Yan Fu , Juan Fu , Qin Liu , Meidan Wang , Pei Liu , Hui He , Haili Zhang , Hongyu Liao , Yangyan Ge , Shuqin Lu , Jinqiang Zhang

Background

Enhancing stress resilience through hippocampal neural stem cell (NSC) activation is a promising way to reduce depression risk. Earlier studies show that asperosaponin Ⅵ (ASA-VI) can efficiently cross the blood-brain barrier and provide neuroprotective benefits, but its role in activating NSC and improving stress resilience has not been explored.

Purpose

This study aims to explore the therapeutic potential and molecular mechanisms of ASA-VI in enhancing stress resilience through hippocampal NSC activation.

Methods

We compared the hippocampal neurogenesis between high-stress resilience (HSR) mice and low-stress resilience (LSR) mice using immunohistochemistry, and explored the role of neurogenesis in maintaining stress resilience by inhibiting NSC activation with temozolomide. We evaluated the effect of ASA-VI on NSC proliferation and differentiation using both in vitro and in vivo investigations. Comprehensive methodologies, including hippocampal transcriptome analysis, western blotting, immunolocalization and pharmacological blocker treatment, were utilized to identify the involvement of the PI3K/Akt pathway in ASA-VI activating NSC.

Results

HSR mice had more Ki67+-GFAP+ cells, BrdU+-DCX+ cells, and BrdU+-NeuN+ cells in hippocampus than LSR mice. Inhibiting NSC activation with temozolomide reduced stress resilience and worsened depressive symptoms in CMS-exposed mice. We also found that ASA-VI strongly promoted NSC proliferation and neuronal differentiation in vitro. In CMS mice, ASA-VI prevented stress-induced impairments in neurogenesis at all stages, from NSC activation to neuron maturation. Consequently, ASA-VI significantly increased the proportion of stress-resilient mice and alleviated depressive-like behaviors. Transcriptomic and biochemical analyses revealed that ASA-VI activates the PI3K/Akt signaling pathway in NSC. Notably, the pro-neurogenic and resilience-enhancing effects of ASA-VI were eliminated by the PI3K inhibitor LY294002.

Conclusion

Our findings identify ASA-VI as a novel agent that enhances stress resilience and prevents depression by activating the PI3K/Akt pathway in NSC.
通过激活海马神经干细胞(NSC)增强应激恢复能力是降低抑郁症风险的一种很有前景的方法。早期的研究表明,asperosaponinⅥ(ASA-VI)可以有效地穿过血脑屏障并提供神经保护作用,但其在激活NSC和提高应激恢复能力方面的作用尚未被探索。目的探讨ASA-VI通过激活海马NSC增强应激恢复的治疗潜力和分子机制。方法采用免疫组化方法比较高应激恢复(HSR)小鼠和低应激恢复(LSR)小鼠海马神经发生的变化,探讨替莫唑胺抑制NSC激活对维持应激恢复的作用。我们通过体外和体内研究评估了ASA-VI对NSC增殖和分化的影响。利用海马转录组分析、western blotting、免疫定位和药物阻断剂治疗等综合方法,确定PI3K/Akt通路参与ASA-VI激活NSC。结果与LSR小鼠相比,shsr小鼠海马组织中Ki67+-GFAP+细胞、BrdU+-DCX+细胞和BrdU+-NeuN+细胞较多。替莫唑胺抑制cms暴露小鼠的NSC激活可降低应激恢复能力并加重抑郁症状。我们还发现ASA-VI对体外培养的NSC增殖和神经元分化有明显的促进作用。在CMS小鼠中,ASA-VI可在从NSC激活到神经元成熟的所有阶段阻止应激诱导的神经发生损伤。因此,ASA-VI显著增加了应激恢复小鼠的比例,减轻了抑郁样行为。转录组学和生化分析表明,ASA-VI激活NSC中PI3K/Akt信号通路。值得注意的是,ASA-VI的前神经源性和弹性增强作用被PI3K抑制剂LY294002消除。结论ASA-VI是一种通过激活NSC中PI3K/Akt通路来增强应激恢复能力和预防抑郁的新型药物。
{"title":"Asperosaponin VI enhances stress resilience by activating hippocampal neural stem cells","authors":"Yu-e Liu ,&nbsp;Yan Fu ,&nbsp;Juan Fu ,&nbsp;Qin Liu ,&nbsp;Meidan Wang ,&nbsp;Pei Liu ,&nbsp;Hui He ,&nbsp;Haili Zhang ,&nbsp;Hongyu Liao ,&nbsp;Yangyan Ge ,&nbsp;Shuqin Lu ,&nbsp;Jinqiang Zhang","doi":"10.1016/j.phymed.2026.157874","DOIUrl":"10.1016/j.phymed.2026.157874","url":null,"abstract":"<div><h3>Background</h3><div>Enhancing stress resilience through hippocampal neural stem cell (NSC) activation is a promising way to reduce depression risk. Earlier studies show that asperosaponin Ⅵ (ASA-VI) can efficiently cross the blood-brain barrier and provide neuroprotective benefits, but its role in activating NSC and improving stress resilience has not been explored.</div></div><div><h3>Purpose</h3><div>This study aims to explore the therapeutic potential and molecular mechanisms of ASA-VI in enhancing stress resilience through hippocampal NSC activation.</div></div><div><h3>Methods</h3><div>We compared the hippocampal neurogenesis between high-stress resilience (HSR) mice and low-stress resilience (LSR) mice using immunohistochemistry, and explored the role of neurogenesis in maintaining stress resilience by inhibiting NSC activation with temozolomide. We evaluated the effect of ASA-VI on NSC proliferation and differentiation using both <em>in vitro</em> and <em>in vivo</em> investigations. Comprehensive methodologies, including hippocampal transcriptome analysis, western blotting, immunolocalization and pharmacological blocker treatment, were utilized to identify the involvement of the PI3K/Akt pathway in ASA-VI activating NSC.</div></div><div><h3>Results</h3><div>HSR mice had more Ki67<sup>+</sup>-GFAP<sup>+</sup> cells, BrdU<sup>+</sup>-DCX<sup>+</sup> cells, and BrdU<sup>+</sup>-NeuN<sup>+</sup> cells in hippocampus than LSR mice. Inhibiting NSC activation with temozolomide reduced stress resilience and worsened depressive symptoms in CMS-exposed mice. We also found that ASA-VI strongly promoted NSC proliferation and neuronal differentiation <em>in vitro</em>. In CMS mice, ASA-VI prevented stress-induced impairments in neurogenesis at all stages, from NSC activation to neuron maturation. Consequently, ASA-VI significantly increased the proportion of stress-resilient mice and alleviated depressive-like behaviors. Transcriptomic and biochemical analyses revealed that ASA-VI activates the PI3K/Akt signaling pathway in NSC. Notably, the pro-neurogenic and resilience-enhancing effects of ASA-VI were eliminated by the PI3K inhibitor LY294002.</div></div><div><h3>Conclusion</h3><div>Our findings identify ASA-VI as a novel agent that enhances stress resilience and prevents depression by activating the PI3K/Akt pathway in NSC.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"152 ","pages":"Article 157874"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146080567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Afzelin resists UVA damage through autophagy and synergizes with ganoderic acid A to skin photoaging 阿泽林通过自噬抵抗UVA损伤,并与灵芝酸A协同对抗皮肤光老化。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157782
Jia-Hua Zou , Mei-Ling Tai , Bao-Ying Li , Jian-Jun Liu , Zhi-Meng Zhang , Han Wang , Dong-Li Zhang , Zhuang Zhou , Shan-Shan Feng , Man-Mei Li , Zhong Liu

Background

Chronic UVA exposure accelerates photoaging by inducing oxidative stress and mitochondrial dysfunction. Autophagy maintains dermal homeostasis, but its decline promotes aging. Afzelin, a flavonoid with antioxidant activity, has not been fully studied for its autophagy-related photoprotective effects.

Purpose

To determine whether afzelin protects against UVA-induced photoaging through autophagy and mitophagy activation, and to assess its synergy with ganoderic acid A (GAA), a triterpenoid possessing established anti-aging activity.

Methods

UVA-irradiated and D-galactose–induced senescence models of human dermal fibroblasts were examined by Western blotting, immunofluorescence, and flow cytometry. A 20-day UVA mouse model evaluated topical efficacy. Synergy was calculated using the Bliss model.

Results

Afzelin restored UVA-impaired cell viability and reduced β-galactosidase, p53, and p21 while recovering Lamin B1. It lowered ROS levels and restored mitochondrial membrane potential (2.8-fold) via AMPK–AKT/mTOR–ULK1 and PINK1–Parkin activation. Combined with GAA (50 mM), afzelin showed strong synergy (Bliss = 67.6 ± 5.1). In vivo, co-treatment reduced epidermal thickness (∼37.3 %), restored collagen I and elastin, and suppressed p53/p21 expression.

Conclusion

Afzelin alleviates UVA-induced photodamage by activating autophagy and mitophagy. Together with the anti-aging triterpenoid GAA, it exerts synergistic anti-photoaging effects, supporting its potential as a natural autophagy-targeting agent for skin rejuvenation.
背景:慢性UVA暴露通过诱导氧化应激和线粒体功能障碍加速光老化。自噬维持皮肤稳态,但其下降促进衰老。黄芩苷是一种具有抗氧化活性的类黄酮,其自噬相关的光保护作用尚未得到充分的研究。目的:研究阿泽林是否通过自噬和自噬激活来防止uva诱导的光老化,并评价其与具有抗衰老活性的三萜灵芝酸A (GAA)的协同作用。方法:采用Western blotting、免疫荧光和流式细胞术检测uva辐照和d -半乳糖诱导的人真皮成纤维细胞衰老模型。用20天的UVA小鼠模型评估局部疗效。使用Bliss模型计算协同效应。结果:Afzelin恢复uva损伤的细胞活力,降低β-半乳糖苷酶、p53和p21,同时恢复Lamin B1。通过AMPK-AKT/mTOR-ULK1和PINK1-Parkin激活,降低ROS水平,恢复线粒体膜电位(2.8倍)。与GAA (50 mM)联合,afzelin表现出较强的协同作用(Bliss = 67.6±5.1)。在体内,共处理减少了表皮厚度(约37.3%),恢复了I型胶原和弹性蛋白,抑制了p53/p21的表达。结论:阿夫泽林通过激活自噬和有丝自噬来减轻uva诱导的光损伤。与抗衰老三萜GAA一起,它具有协同抗光老化作用,支持其作为皮肤再生的天然自噬靶向剂的潜力。
{"title":"Afzelin resists UVA damage through autophagy and synergizes with ganoderic acid A to skin photoaging","authors":"Jia-Hua Zou ,&nbsp;Mei-Ling Tai ,&nbsp;Bao-Ying Li ,&nbsp;Jian-Jun Liu ,&nbsp;Zhi-Meng Zhang ,&nbsp;Han Wang ,&nbsp;Dong-Li Zhang ,&nbsp;Zhuang Zhou ,&nbsp;Shan-Shan Feng ,&nbsp;Man-Mei Li ,&nbsp;Zhong Liu","doi":"10.1016/j.phymed.2026.157782","DOIUrl":"10.1016/j.phymed.2026.157782","url":null,"abstract":"<div><h3>Background</h3><div>Chronic UVA exposure accelerates photoaging by inducing oxidative stress and mitochondrial dysfunction. Autophagy maintains dermal homeostasis, but its decline promotes aging. Afzelin, a flavonoid with antioxidant activity, has not been fully studied for its autophagy-related photoprotective effects.</div></div><div><h3>Purpose</h3><div>To determine whether afzelin protects against UVA-induced photoaging through autophagy and mitophagy activation, and to assess its synergy with ganoderic acid A (GAA), a triterpenoid possessing established anti-aging activity.</div></div><div><h3>Methods</h3><div>UVA-irradiated and D-galactose–induced senescence models of human dermal fibroblasts were examined by Western blotting, immunofluorescence, and flow cytometry. A 20-day UVA mouse model evaluated topical efficacy. Synergy was calculated using the Bliss model.</div></div><div><h3>Results</h3><div>Afzelin restored UVA-impaired cell viability and reduced β-galactosidase, p53, and p21 while recovering Lamin B1. It lowered ROS levels and restored mitochondrial membrane potential (2.8-fold) via AMPK–AKT/mTOR–ULK1 and PINK1–Parkin activation. Combined with GAA (50 mM), afzelin showed strong synergy (Bliss = 67.6 ± 5.1). <em>In vivo</em>, co-treatment reduced epidermal thickness (∼37.3 %), restored collagen I and elastin, and suppressed p53/p21 expression.</div></div><div><h3>Conclusion</h3><div>Afzelin alleviates UVA-induced photodamage by activating autophagy and mitophagy. Together with the anti-aging triterpenoid GAA, it exerts synergistic anti-photoaging effects, supporting its potential as a natural autophagy-targeting agent for skin rejuvenation.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"153 ","pages":"Article 157782"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phillyrin ameliorates sepsis via targeting microRNA-203a-mediated caspase-4/caspase-11/caspase-B downregulation to suppress endothelial pyroptosis philyrin通过靶向microrna -203a介导的caspase-4/caspase-11/caspase-B下调抑制内皮细胞焦亡来改善脓毒症。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157872
Xiangjun Zhou , Guangli Yang , Weifu Tan , Hongyan Ding , Wujuan Zheng , Yong Liu , Liyi Zou , Xiaohua Su , Linzhong Yu , Wei Li , Liling Yang

Background

Sepsis, driven by dysregulated host inflammation, remains a leading cause of global mortality and lacks sufficiently effective therapies. Phillyrin (PHN), a lignan glycoside from Forsythia suspensa (Thunb.) Vahl (Oleaceae), exhibits anti-inflammatory and antimicrobial properties. However, its molecular mechanism in sepsis remains poorly understood.

Objective

To delineate the molecular pathways by which PHN mitigates sepsis.

Methods

Reverse transcription-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, cytotoxicity assessments, and calcein acetoxymethyl ester/propidium iodide staining were employed to evaluate the protective effects of PHN against lipopolysaccharide (LPS)-mediated pyroptosis in human pulmonary microvascular endothelial cells (HPMECs). Network pharmacology and integrative bioinformatics were used to identify candidate regulatory axes. Findings were then validated across multiple models: HPMEC-differentiated human promyelocytic acute leukemia cell co-cultures systems, Tg(mpx:GFP) zebrafish, and BALB/c mice. Validation techniques comprised luciferase reporters, pharmacological modulators, and morpholino knockdown.

Results

PHN significantly attenuated LPS-induced inflammatory pyroptosis in HPMECs. Evidence included reduced proinflammatory cytokine production, decreased lactate dehydrogenase leakage, and fewer pyroptotic cells. Computational analyses identified the microRNA (miR)-203a-caspase-4 (CASP4) axis as a primary mediator of PHN's anti-septic activity. In co-culture systems, PHN suppressed cytoplasmic LPS-triggered pyroptosis through miR-203a-dependent CASP4 downregulation, thereby reducing inflammatory cytokine secretion and neutrophil recruitment. In LPS-challenged zebrafish, PHN upregulated miR-203a to suppress caspase-B (CASPB), diminishing cytokine expression and neutrophil migration while improving survival. In murine sepsis models induced by LPS or cecal ligation and puncture, PHN modulated the miR-203a-caspase-11 (CASP11) axis to confer multiple therapeutic benefits. These included improved survival rates, stabilized body temperature, reduced bronchoalveolar lavage protein levels and neutrophil infiltration, attenuated multi-organ injury, and decreased systemic cytokine levels.

Conclusion

These data identify the miR-203a-CASP4/11/B axis as a critical mediator of endothelial pyroptosis in sepsis. PHN attenuates sepsis by upregulating miR-203a to inhibit CASP4/11/B-dependent pyroptosis. Therefore, PHN warrants further investigation as a potential therapeutic agent for sepsis.
背景:由宿主炎症失调引起的败血症仍然是全球死亡的主要原因,缺乏足够有效的治疗方法。连翘苷(PHN),一种来自连翘的木脂素苷。Vahl(油菜科),具有抗炎和抗菌特性。然而,其在脓毒症中的分子机制尚不清楚。目的:探讨PHN减轻脓毒症的分子途径。方法:采用逆转录-定量聚合酶链反应、酶联免疫吸附法、细胞毒性评价、钙黄蛋白乙酰氧基甲酯/碘化丙啶染色法评价PHN对脂多糖(LPS)介导的人肺微血管内皮细胞(hpmes)焦亡的保护作用。网络药理学和综合生物信息学用于确定候选调控轴。研究结果随后在多个模型中得到验证:hpmec分化的人早幼粒细胞急性白血病细胞共培养系统、Tg(mpx:GFP)斑马鱼和BALB/c小鼠。验证技术包括荧光素酶报告,药理学调节剂和morpholino敲除。结果:PHN能显著减弱lps诱导的hpmec炎性焦亡。证据包括促炎细胞因子产生减少,乳酸脱氢酶渗漏减少,焦亡细胞减少。计算分析发现microRNA (miR)-203a-caspase-4 (CASP4)轴是PHN抗菌活性的主要介质。在共培养系统中,PHN通过下调mir -203a依赖性CASP4抑制细胞质lps引发的焦亡,从而减少炎症细胞因子分泌和中性粒细胞募集。在lps挑战的斑马鱼中,PHN上调miR-203a抑制caspase-B (CASPB),减少细胞因子表达和中性粒细胞迁移,同时提高生存。在LPS或盲肠结扎和穿刺诱导的小鼠脓毒症模型中,PHN调节miR-203a-caspase-11 (CASP11)轴,从而获得多种治疗益处。这些包括提高生存率,稳定体温,减少支气管肺泡灌洗蛋白水平和中性粒细胞浸润,减轻多器官损伤,降低全身细胞因子水平。结论:这些数据确定miR-203a-CASP4/11/B轴是脓毒症中内皮细胞焦亡的关键介质。PHN通过上调miR-203a抑制CASP4/11/ b依赖性焦亡来减轻脓毒症。因此,PHN作为脓毒症的潜在治疗剂值得进一步研究。
{"title":"Phillyrin ameliorates sepsis via targeting microRNA-203a-mediated caspase-4/caspase-11/caspase-B downregulation to suppress endothelial pyroptosis","authors":"Xiangjun Zhou ,&nbsp;Guangli Yang ,&nbsp;Weifu Tan ,&nbsp;Hongyan Ding ,&nbsp;Wujuan Zheng ,&nbsp;Yong Liu ,&nbsp;Liyi Zou ,&nbsp;Xiaohua Su ,&nbsp;Linzhong Yu ,&nbsp;Wei Li ,&nbsp;Liling Yang","doi":"10.1016/j.phymed.2026.157872","DOIUrl":"10.1016/j.phymed.2026.157872","url":null,"abstract":"<div><h3>Background</h3><div>Sepsis, driven by dysregulated host inflammation, remains a leading cause of global mortality and lacks sufficiently effective therapies. Phillyrin (PHN), a lignan glycoside from <em>Forsythia suspensa</em> (Thunb.) Vahl (Oleaceae), exhibits anti-inflammatory and antimicrobial properties. However, its molecular mechanism in sepsis remains poorly understood.</div></div><div><h3>Objective</h3><div>To delineate the molecular pathways by which PHN mitigates sepsis.</div></div><div><h3>Methods</h3><div>Reverse transcription-quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, cytotoxicity assessments, and calcein acetoxymethyl ester/propidium iodide staining were employed to evaluate the protective effects of PHN against lipopolysaccharide (LPS)-mediated pyroptosis in human pulmonary microvascular endothelial cells (HPMECs). Network pharmacology and integrative bioinformatics were used to identify candidate regulatory axes. Findings were then validated across multiple models: HPMEC-differentiated human promyelocytic acute leukemia cell co-cultures systems, <em>Tg(mpx:GFP)</em> zebrafish, and BALB/c mice. Validation techniques comprised luciferase reporters, pharmacological modulators, and morpholino knockdown.</div></div><div><h3>Results</h3><div>PHN significantly attenuated LPS-induced inflammatory pyroptosis in HPMECs. Evidence included reduced proinflammatory cytokine production, decreased lactate dehydrogenase leakage, and fewer pyroptotic cells. Computational analyses identified the microRNA (miR)-203a-caspase-4 (CASP4) axis as a primary mediator of PHN's anti-septic activity. In co-culture systems, PHN suppressed cytoplasmic LPS-triggered pyroptosis through miR-203a-dependent CASP4 downregulation, thereby reducing inflammatory cytokine secretion and neutrophil recruitment. In LPS-challenged zebrafish, PHN upregulated miR-203a to suppress caspase-B (CASPB), diminishing cytokine expression and neutrophil migration while improving survival. In murine sepsis models induced by LPS or cecal ligation and puncture, PHN modulated the miR-203a-caspase-11 (CASP11) axis to confer multiple therapeutic benefits. These included improved survival rates, stabilized body temperature, reduced bronchoalveolar lavage protein levels and neutrophil infiltration, attenuated multi-organ injury, and decreased systemic cytokine levels.</div></div><div><h3>Conclusion</h3><div>These data identify the miR-203a-CASP4/11/B axis as a critical mediator of endothelial pyroptosis in sepsis. PHN attenuates sepsis by upregulating miR-203a to inhibit CASP4/11/B-dependent pyroptosis. Therefore, PHN warrants further investigation as a potential therapeutic agent for sepsis.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"152 ","pages":"Article 157872"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semen Sojae Praeparatum ameliorates triptolide-induced liver injury by regulating bile acid homeostasis and the Keap1/Nrf2/p62 axis 黄豆精通过调节胆酸稳态和Keap1/Nrf2/p62轴改善雷公藤甲素诱导的肝损伤
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157878
Lin Zhou , Qi Qian , Yaqin Zhen , Hanyu Ma , Liying Niu , Xinguo Wang

Background

Semen Sojae Praeparatum (SSP) exhibits both preventive and therapeutic effects against drug-induced liver injury (DILI). Traditionally, SSP is used in combination with Gardeniae fructus to prevent its hepatotoxicity. Isoflavones, the primary components of SSP, can mitigate DILI induced by chemotherapeutic agents such as acetaminophen and cisplatin. However, the potential of SSP to alleviate the hepatotoxicity of triptolide (TP, a prototypical compound in DILI research) remains unexplored.

Purpose

This study aimed to explore the protective effects and potential mechanisms of SSP on TP-induced liver injury.

Methods

The phytochemical profile of the SSP extracts was characterized using UPLC-Q-TOF-MS. Hepatoprotective effects of SSP were assessed using a TP-induced liver injury mouse model. The mechanisms were predicted by metabolomic and proteomic analyses, and further elucidated by RT-qPCR, western blotting and transmission electron microscopy.

Results

Isoflavones were identified as the main components of the SSP extracts. SSP treatment alleviated TP-induced abnormalities in serum biochemical markers, liver index and pathological damage. Multi-omics analysis revealed SSP modulated bile acid (BA) metabolism and autophagy, with Keap1 serving as a core protein. Furthermore, SSP reduced intrahepatic BA accumulation by enhancing hepatic BA transport rather than inhibiting BA synthesis. Additionally, SSP reversed TP-induced abnormalities in Keap1 and p62 expression and nuclear translon cation of the Nrf2 transcription factor, and mitigated oxidative imbalance and autophagic cell death.

Conclusions

SSP ameliorated TP-induced liver injury by modulating bile acid homeostasis and the Keap1/Nrf2/p62 pathway, thereby alleviating oxidative stress and excessive autophagy.
黄豆精(SSP)对药物性肝损伤(DILI)具有预防和治疗双重作用。传统上,SSP与栀子联合使用,以防止其肝毒性。SSP的主要成分异黄酮可以减轻对乙酰氨基酚和顺铂等化疗药物引起的DILI。然而,SSP减轻雷公藤甲素(TP, DILI研究中的一种典型化合物)肝毒性的潜力仍未被探索。目的探讨SSP对tp性肝损伤的保护作用及其可能机制。方法采用UPLC-Q-TOF-MS对SSP提取物的植物化学特征进行表征。采用tp诱导的肝损伤小鼠模型,评估了SSP的肝保护作用。通过代谢组学和蛋白质组学分析预测了其机制,并通过RT-qPCR、western blotting和透射电镜进一步阐明了其机制。结果黄芪提取物的主要成分为异黄酮。SSP治疗可减轻tp引起的血清生化指标、肝脏指数异常及病理损伤。多组学分析显示,SSP调节胆汁酸(BA)代谢和自噬,其中Keap1是核心蛋白。此外,SSP通过增强肝脏BA转运而不是抑制BA合成来减少肝内BA积累。此外,SSP逆转了tp诱导的Keap1和p62表达异常以及Nrf2转录因子的核翻译阳离子,减轻了氧化失衡和自噬细胞死亡。结论sssp通过调节胆胆酸稳态和Keap1/Nrf2/p62通路改善tp诱导的肝损伤,从而减轻氧化应激和过度自噬。
{"title":"Semen Sojae Praeparatum ameliorates triptolide-induced liver injury by regulating bile acid homeostasis and the Keap1/Nrf2/p62 axis","authors":"Lin Zhou ,&nbsp;Qi Qian ,&nbsp;Yaqin Zhen ,&nbsp;Hanyu Ma ,&nbsp;Liying Niu ,&nbsp;Xinguo Wang","doi":"10.1016/j.phymed.2026.157878","DOIUrl":"10.1016/j.phymed.2026.157878","url":null,"abstract":"<div><h3>Background</h3><div>Semen Sojae Praeparatum (SSP) exhibits both preventive and therapeutic effects against drug-induced liver injury (DILI). Traditionally, SSP is used in combination with <em>Gardeniae fructus</em> to prevent its hepatotoxicity. Isoflavones, the primary components of SSP, can mitigate DILI induced by chemotherapeutic agents such as acetaminophen and cisplatin. However, the potential of SSP to alleviate the hepatotoxicity of triptolide (TP, a prototypical compound in DILI research) remains unexplored.</div></div><div><h3>Purpose</h3><div>This study aimed to explore the protective effects and potential mechanisms of SSP on TP-induced liver injury.</div></div><div><h3>Methods</h3><div>The phytochemical profile of the SSP extracts was characterized using UPLC-Q-TOF-MS. Hepatoprotective effects of SSP were assessed using a TP-induced liver injury mouse model. The mechanisms were predicted by metabolomic and proteomic analyses, and further elucidated by RT-qPCR, western blotting and transmission electron microscopy.</div></div><div><h3>Results</h3><div>Isoflavones were identified as the main components of the SSP extracts. SSP treatment alleviated TP-induced abnormalities in serum biochemical markers, liver index and pathological damage. Multi-omics analysis revealed SSP modulated bile acid (BA) metabolism and autophagy, with Keap1 serving as a core protein. Furthermore, SSP reduced intrahepatic BA accumulation by enhancing hepatic BA transport rather than inhibiting BA synthesis. Additionally, SSP reversed TP-induced abnormalities in Keap1 and p62 expression and nuclear translon cation of the Nrf2 transcription factor, and mitigated oxidative imbalance and autophagic cell death.</div></div><div><h3>Conclusions</h3><div>SSP ameliorated TP-induced liver injury by modulating bile acid homeostasis and the Keap1/Nrf2/p62 pathway, thereby alleviating oxidative stress and excessive autophagy.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"153 ","pages":"Article 157878"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146192028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GuBen AnTai decoction ameliorates recurrent spontaneous abortion by suppressing excessive autophagy via EGFR/PI3K pathway modulation. 固本安泰汤通过调节EGFR/PI3K通路抑制过度自噬,改善复发性自然流产。
IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2026-01-22 DOI: 10.1016/j.phymed.2026.157864
Mingyue Han, Zhuoxuan Su, Bingyao Yang, Xuebing Li, Dan Wang, Xin Zhang, Xin Du, Qiqi Fu, Chunxia Wang, Yongwei Li

Background: The Chinese herbal formula Guben Antai Decoction (GBAT) demonstrates efficacy in reducing pregnancy loss associated with recurrent spontaneous abortion (RSA). However, the molecular mechanisms underlying its impact on the physiological functions of the placental trophoblast cells remain unclear.

Purpose: The objectives were to assess GBAT's efficacy in both a trophoblast-cell oxidative-stress model and a pregnant mouse model of RSA and to elucidate the complex mechanisms underlying the prevention of pregnancy loss using comprehensive multi-omics analysis integrated with a network pharmacology framework.

Materials and methods: Network pharmacology and bioinformatics were used to screen key GBAT targets associated with regulating autophagy and improving RSA. We established an RSA pregnant mouse model (CBA/J x DBA/2) comprising normal, RSA, low-dose GBAT (L-GBAT), high-dose GBAT (H-GBAT), and Dydrogesterone (DYD) groups. The maternal-fetal interface was analyzed at the autophagy level by performing HE staining, immunohistochemistry, transmission electron microscopy, and western blotting. We treated HTR-8/Svneo cells with H₂O₂ (40 μM, 3 h) to establish a trophoblast cell oxidative damage model with the following groups: control, H₂O₂, H₂O₂+GBAT, H₂O₂+GBAT+RAPA (autophagy activator), and H₂O₂+GBAT+Gefitinib (EGFR inhibitor). We performed drug-containing serum interventions in these groups and examined GBAT's modulation of autophagic activity and EGFR/PI3K phosphorylation via western blotting, MDC assay, and immunofluorescence.

Results: Network pharmacology and bioinformatics analyses showed that the EGFR/PI3K signaling pathway was an important mediator of GBAT-induced RSA autophagy. In vivo, GBAT inhibited autophagy and downregulated EGFR/PI3K phosphorylation in the Placental tissue placental villi of the RSA mice, which improved pregnancy outcomes. In vitro, GBAT-containing serum inhibited autophagy in oxidatively stressed HTR-8/Svneo cells. This effect was partially reversed by RAPA or gefitinib treatment.

Conclusions: GBAT may effectively inhibit excessive autophagic activation in RSA. The EGFR/PI3K pathway plays an important role in its therapeutic efficacy. Thus, GBAT is a promising candidate for alleviating RSA-induced miscarriage.

背景:中药固本安泰汤(GBAT)具有减少复发性自然流产(RSA)导致的妊娠丢失的疗效。然而,其影响胎盘滋养细胞生理功能的分子机制尚不清楚。目的:目的是评估GBAT在滋养细胞氧化应激模型和RSA妊娠小鼠模型中的功效,并通过综合多组学分析和网络药理学框架阐明其预防妊娠丢失的复杂机制。材料和方法:利用网络药理学和生物信息学技术筛选与调节自噬和改善RSA相关的关键GBAT靶点。我们建立了RSA妊娠小鼠模型(CBA/J x DBA/2),包括正常组、RSA组、低剂量GBAT组(L-GBAT)、高剂量GBAT组(H-GBAT)和地屈孕酮组(DYD)。通过HE染色、免疫组织化学、透射电镜和western blotting分析自噬水平的母胎界面。我们将HTR-8/Svneo细胞用40 μM的H₂O₂(3 H)处理,建立滋养细胞氧化损伤模型,分为对照组、H₂O₂、H₂O₂+GBAT、H₂O₂+GBAT+RAPA(自噬激活剂)、H₂O₂+GBAT+吉非替尼(EGFR抑制剂)。我们对这些组进行了含药物的血清干预,并通过western blotting、MDC测定和免疫荧光检测了GBAT对自噬活性和EGFR/PI3K磷酸化的调节。结果:网络药理学和生物信息学分析表明,EGFR/PI3K信号通路是gbat诱导的RSA自噬的重要介质。在体内,GBAT抑制了RSA小鼠胎盘组织的自噬,下调了胎盘绒毛中EGFR/PI3K的磷酸化,从而改善了妊娠结局。在体外,含gbat的血清可抑制氧化应激HTR-8/Svneo细胞的自噬。RAPA或吉非替尼治疗可部分逆转这种效应。结论:GBAT可有效抑制RSA过度自噬激活。EGFR/PI3K通路在其治疗效果中起重要作用。因此,GBAT是缓解rsa诱导流产的有希望的候选药物。
{"title":"GuBen AnTai decoction ameliorates recurrent spontaneous abortion by suppressing excessive autophagy via EGFR/PI3K pathway modulation.","authors":"Mingyue Han, Zhuoxuan Su, Bingyao Yang, Xuebing Li, Dan Wang, Xin Zhang, Xin Du, Qiqi Fu, Chunxia Wang, Yongwei Li","doi":"10.1016/j.phymed.2026.157864","DOIUrl":"https://doi.org/10.1016/j.phymed.2026.157864","url":null,"abstract":"<p><strong>Background: </strong>The Chinese herbal formula Guben Antai Decoction (GBAT) demonstrates efficacy in reducing pregnancy loss associated with recurrent spontaneous abortion (RSA). However, the molecular mechanisms underlying its impact on the physiological functions of the placental trophoblast cells remain unclear.</p><p><strong>Purpose: </strong>The objectives were to assess GBAT's efficacy in both a trophoblast-cell oxidative-stress model and a pregnant mouse model of RSA and to elucidate the complex mechanisms underlying the prevention of pregnancy loss using comprehensive multi-omics analysis integrated with a network pharmacology framework.</p><p><strong>Materials and methods: </strong>Network pharmacology and bioinformatics were used to screen key GBAT targets associated with regulating autophagy and improving RSA. We established an RSA pregnant mouse model (CBA/J x DBA/2) comprising normal, RSA, low-dose GBAT (L-GBAT), high-dose GBAT (H-GBAT), and Dydrogesterone (DYD) groups. The maternal-fetal interface was analyzed at the autophagy level by performing HE staining, immunohistochemistry, transmission electron microscopy, and western blotting. We treated HTR-8/Svneo cells with H₂O₂ (40 μM, 3 h) to establish a trophoblast cell oxidative damage model with the following groups: control, H₂O₂, H₂O₂+GBAT, H₂O₂+GBAT+RAPA (autophagy activator), and H₂O₂+GBAT+Gefitinib (EGFR inhibitor). We performed drug-containing serum interventions in these groups and examined GBAT's modulation of autophagic activity and EGFR/PI3K phosphorylation via western blotting, MDC assay, and immunofluorescence.</p><p><strong>Results: </strong>Network pharmacology and bioinformatics analyses showed that the EGFR/PI3K signaling pathway was an important mediator of GBAT-induced RSA autophagy. In vivo, GBAT inhibited autophagy and downregulated EGFR/PI3K phosphorylation in the Placental tissue placental villi of the RSA mice, which improved pregnancy outcomes. In vitro, GBAT-containing serum inhibited autophagy in oxidatively stressed HTR-8/Svneo cells. This effect was partially reversed by RAPA or gefitinib treatment.</p><p><strong>Conclusions: </strong>GBAT may effectively inhibit excessive autophagic activation in RSA. The EGFR/PI3K pathway plays an important role in its therapeutic efficacy. Thus, GBAT is a promising candidate for alleviating RSA-induced miscarriage.</p>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":" ","pages":"157864"},"PeriodicalIF":8.3,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Phytomedicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1